SecurityATRS / Antares Pharma, Inc. (036642106)
IndustrySurgical and Medical Instruments and Apparatus
Common Stock Shares Outstanding157,437,000 shares (as of 2018-06-30)
Total Insiders19
Total Directors8
Total Officers7

Stock Insider Trading (from SEC Form 4)

Antares Pharma, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

ATRS / Antares Pharma, Inc. insiders include HOBBS EAMONN P, Tursi James Patrick, Stacey Jennifer Evans, DEERFIELD PARTNERS, L.P., and APPLE ROBERT F, GRAHAM PETER J, ROCHE ROBERT P JR, Deerfield International Master Fund, L.P. Deerfield Mgmt L.P., Powell Fred M, GARRITY THOMAS J, GONELLA JACQUES, SAMSON MARVIN, Fickenscher James E, JACOB LEONARD S, Flynn James E, Deerfield Special Situations Fund, L.P., GUETH ANTON, DEERFIELD MANAGEMENT CO, .

Insider Roster

Insider Dir Off 10% Shares Owned
GONELLA JACQUES Director
X 9,985,848
Tursi James Patrick EVP, Chief Medical Officer
X
APPLE ROBERT F President & CEO, Director
X X 1,530,562
GUETH ANTON Director
X
GARRITY THOMAS J Director
X
GRAHAM PETER J EVP General Counsel, Secretary
X 289,173
Powell Fred M Executive Vice President & CFO
X 413,492
SAMSON MARVIN Director
X
ROCHE ROBERT P JR Director
X
JACOB LEONARD S Director
X
Fickenscher James E Senior Vice President & CFO
X
Flynn James E 10% Owner
Deerfield Mgmt L.P. 10% Owner
DEERFIELD MANAGEMENT CO 10% Owner
Deerfield International Master Fund, L.P. 10% Owner
DEERFIELD PARTNERS, L.P. 10% Owner
Deerfield Special Situations Fund, L.P. 10% Owner
X
HOBBS EAMONN P President & CEO, Director
X X
DEERFIELD PARTNERS, L.P. 10% Owner
Deerfield International Master Fund, L.P. 10% Owner
Flynn James E 10% Owner
Deerfield Mgmt L.P. 10% Owner
DEERFIELD MANAGEMENT CO 10% Owner
X
DEERFIELD MANAGEMENT CO 10% Owner
Deerfield International Master Fund, L.P. 10% Owner
Flynn James E 10% Owner
Deerfield Mgmt L.P. 10% Owner
DEERFIELD PARTNERS, L.P. 10% Owner
X
Deerfield International Master Fund, L.P. 10% Owner
DEERFIELD PARTNERS, L.P. 10% Owner
Deerfield Special Situations Fund, L.P. 10% Owner
DEERFIELD MANAGEMENT CO 10% Owner
Deerfield Mgmt L.P. 10% Owner
Flynn James E 10% Owner
X
Deerfield Mgmt L.P. 10% Owner
Deerfield International Master Fund, L.P. 10% Owner
DEERFIELD PARTNERS, L.P. 10% Owner
Deerfield Special Situations Fund, L.P. 10% Owner
DEERFIELD MANAGEMENT CO 10% Owner
Flynn James E 10% Owner
X
Deerfield Special Situations Fund, L.P. 10% Owner
Flynn James E 10% Owner
Deerfield Mgmt L.P. 10% Owner
Deerfield International Master Fund, L.P. 10% Owner
DEERFIELD PARTNERS, L.P. 10% Owner
DEERFIELD MANAGEMENT CO 10% Owner
X
Stacey Jennifer Evans SVP, General Counsel & Secty
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-08-13 4 GONELLA JACQUES S D 3.09 -49,507 9,985,848 30,856,270
2018-08-08 4 GONELLA JACQUES S D 3.09 -250,493 10,035,355 31,009,247
2018-06-15 4 GONELLA JACQUES S D 2.95 -565 10,285,848 30,343,252
2018-06-12 4 GONELLA JACQUES S D 2.77 -100,000 10,286,413 28,493,364
2018-06-11 4 GONELLA JACQUES S D 2.69 -100,000 10,386,413 27,939,451
2018-06-08 4 Powell Fred M A D 2.70 91,667 413,492
2018-06-07 4 Powell Fred M F D 2.70 -9,609 321,825
2018-06-08 4 GRAHAM PETER J A D 2.70 91,667 289,173
2018-06-07 4 GRAHAM PETER J F D 2.70 -12,923 197,506
2018-06-08 4 APPLE ROBERT F A D 2.70 305,556 1,530,562
2018-06-07 4 APPLE ROBERT F F D 2.70 -32,031 1,225,006
2018-06-06 4 GONELLA JACQUES S D 2.70 -20,259 10,486,413 28,313,315
2018-06-05 4 GONELLA JACQUES S D 2.70 -23,129 10,506,672 28,368,014
2018-06-02 4 GRAHAM PETER J F D 2.69 -15,422 210,429
2018-06-02 4 APPLE ROBERT F F D 2.69 -34,402 1,257,037
2018-06-05 4 GONELLA JACQUES S D 2.55 -100,000 10,529,801 26,850,993
2018-06-04 4 GONELLA JACQUES S D 2.65 -100,000 10,629,801 28,168,973
2018-06-01 4 GONELLA JACQUES S D 2.70 -56,612 10,729,801 28,970,463
2018-06-01 4 GONELLA JACQUES S D 2.60 -78,938 10,786,413 28,044,674
2018-05-30 4 GONELLA JACQUES S D 2.55 -100,000 10,865,351 27,706,645
2018-05-28 4 APPLE ROBERT F F D 2.43 -13,480 1,291,439
2018-05-23 4 GONELLA JACQUES S D 2.50 -100,000 10,965,351 27,413,378
2018-05-23 4 GONELLA JACQUES S D 2.53 -94,682 11,065,351 27,995,338
2018-05-22 4 GONELLA JACQUES S D 2.53 -5,318 11,160,033 28,234,883
2018-05-18 4 GONELLA JACQUES S D 2.60 -21,062 11,165,351 29,029,913
2018-05-17 4 GONELLA JACQUES S D 2.55 -100,000 11,186,413 28,525,353
2018-05-16 4 GONELLA JACQUES S D 2.52 -100,000 11,286,413 28,441,761
2018-05-15 4 GONELLA JACQUES S D 2.50 -100,000 11,386,413 28,466,032
2018-05-14 4 GONELLA JACQUES S D 2.50 -100,000 11,486,413 28,716,032
2018-05-11 4 GONELLA JACQUES S D 2.47 -100,000 11,586,413 28,618,440
2018-05-10 4 GONELLA JACQUES S D 2.36 -100,000 11,686,413 27,579,935
2018-05-11 4 APPLE ROBERT F F D 2.52 -30,052 1,304,919
2018-05-11 4 APPLE ROBERT F M D 0.85 82,500 1,334,971
2018-05-09 4 GONELLA JACQUES S D 2.4746 -150,000 11,786,413 29,166,658
2018-05-09 4 GONELLA JACQUES S D 2.4614 -150,000 11,936,413 29,380,287
2018-05-03 4 GONELLA JACQUES M D 0.85 30,000 12,086,413
2018-03-29 4 JACOB LEONARD S M D 0.85 32,407 239,892
2018-02-22 4 APPLE ROBERT F F D 2.20 -37,001 1,252,471
2018-02-22 4 APPLE ROBERT F A D 113,835 1,289,472
2017-10-09 4 JACOB LEONARD S S X D 4.0521 -200,000 207,485 840,750
2017-10-09 4 JACOB LEONARD S M X D 0.50 188,600 407,485
2017-10-09 4 JACOB LEONARD S S X D 4.05 -30,000 218,885 886,484
2017-10-09 4 JACOB LEONARD S M X D 0.85 30,000 248,885
2017-10-03 4 GARRITY THOMAS J S X D 3.50 -30,000 160,213 560,746
2017-10-03 4 GARRITY THOMAS J M X D 0.85 30,000 190,213
2017-06-09 4 Powell Fred M P D 2.7944 130,000 331,434 926,159
2017-06-07 4 GRAHAM PETER J A D 2.66 101,434 225,851
2017-06-02 4 GRAHAM PETER J F D 2.57 -16,633 124,417
2017-06-07 4 Powell Fred M A D 2.66 101,434 201,434
2017-06-07 4 APPLE ROBERT F A D 2.66 -338,115 1,175,637
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)
ATRS : Antares Pharma Stock Analysis and Research Report

2017-10-31 - Asif

Antares Pharma, Inc. is an emerging, specialty pharmaceutical company that focuses on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its strategy is to identify new or existing approved drug formulations and apply its drug delivery technology to enhance the drug compounds and delivery methods. The company develop, manufacture and commercialize, for itself or with partners, novel therapeutic products using its advanced drug delivery systems that are designed to help improve safety and efficacy, reduce side effects, and enhance patient comfort and adherence. Its subcutaneous injection technology platforms include the VIBEX® pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-dose pen injectors for use with standard cartridges. Antares Pharma has a portfolio of proprietary and partnered pro...

Related Articles

REPH: Recro Pharma Analysis and Research Report

12h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

13h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

13h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

Related News Stories

Antares Pharma: Proven Business Model Set To Move Much Higher

6h seekingalpha
Management strategy of pursuing a combination of proprietary and partnered drugs is derisking future growth while providing enhanced upside with proprietary offerings. (23-0)

Your Daily Pharma Scoop: Opdivo Is Approved On SCLC, Mateon Trial On Hold, Tandem Product Launch

2018-08-19 seekingalpha
Discussion: Bristol-Myers Squibb's (BMY) OPDIVO (nivolumab) is now FDA approved for patients with metastatic small cell lung cancer (‘SCLC) that has progressed after platinum-based chemo and at least one prior line of therapy. This is the first and till date only FDA-approved Immuno-Oncology treatment option for this patient category. Also because this is the first successful checkpoint inhibitor to be approved for these indications, the researchers consider approval of nivolumab to be “particularly exciting. (20-1)

Antares Pharma Inc. 2018 Q2 - Results - Earnings Call Slides

2018-08-07 seekingalpha
The following slide deck was published by Antares Pharma Inc. in conjunction with their 2018 Q2 earnings call.

Antares Pharma, Inc. (ATRS) CEO Bob Apple on Q2 2018 Results - Earnings Call Transcript

2018-08-07 seekingalpha
Antares Pharma, Inc. (NASDAQ:ATRS) Q2 2018 Results Earnings Conference Call August 7, 2018 8:30 AM ET (2-0)

Swinging For The Fence On Antares Pharma

2018-07-08 seekingalpha
A study from 2009 by Alok Kumar found retail investors exhibit “a greater propensity to gamble” as compared to institutional investors. (62-1)